Compare Best Buy Co Inc (BBY) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs ClearPoint Neuro Inc — how do they compare? Best Buy Co Inc trades at $85.79 (market cap $17.70B), while ClearPoint Neuro Inc trades at $15.69 (market cap $478.63M). The key difference: Best Buy Co Inc is far larger — about 37× ClearPoint Neuro Inc's market cap, and Best Buy Co Inc pays a 4.57% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| BBY | CLPT | |
|---|---|---|
Market Cap | $17.70B | $478.63M |
Sector | Consumer Cyclical | Health |
52-Week High | $84.00 | $29.60 |
52-Week Low | $55.52 | $8.66 |
Enterprise Value | $20.08B | $506.63M |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $81.65, down 1.39% on the day, with a bullish technical outlook and strong recent earnings beats. The stock shows robust profitability with a 39.1% ROE and trades at attractive valuations (P/E 15.12, P/S 0.41). Recent news highlights leadership changes and strategic shifts toward higher-margin businesses like marketplace and retail media, supported by new product launches such as RGB LED TVs and Meta VR partnerships.
The outlook is cautiously optimistic with a consensus price target of $82.17 offering modest upside. Key opportunities include dividend yield near 5% and earnings momentum, while risks involve revenue declines, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is mixed with 34% buy ratings, reflecting balanced views on growth potential versus execution challenges.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
